✨ Free AI Report
Pharming Group N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pharming Group N.V.
Company Research

Pharming Group N.V.: Business Overview, Financials & Competitive Analysis

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovativ...

Analyst-debate audio for Pharming Group N.V.

AskCyborg analysts argue the bull and bear cases for Pharming Group N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Rare disease specialist with market validation and clinical pipeline acceleration positioning for sustainable growth...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Rare Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Pharming Group N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Pharming Group N.V. Overview

Pro stress-test →

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovative medicines including small molecules and biologics. The company is headquartered in Leiden, the Netherlands, and serves patients in over 30 markets globally.

Strategic Profile

Pro stress-test →

Pharming's promotion to the AMX mid-cap index in September 2025 reflects the company's strong growth momentum. The company is focused on executing significant commercial and pipeline catalysts to develop into a leading global rare disease company.

Competitive Landscape

Pro stress-test →

Pharming's lead commercial product RUCONEST is a recombinant human C1-esterase inhibitor for hereditary angioedema treatment. The company competes in the rare disease space with focused portfolios targeting unmet needs in immunodeficiency and complement-mediated disorders, competing against larger pharma and specialty biotech firms with similar disease focus.

Industry Context

Pharming Group N.V. operates in Biopharmaceuticals - Rare Diseases.

Key facts

Founded: 1988 · Headquarters: Leiden, Netherlands

What the analysts stress-tested

The top findings that survived the multi-agent debate for Pharming Group N.V..

  • Promoted to AMX mid-cap index (September 2025) signaling strong commercial and financial momentum
  • Leniolisib in accelerated FDA review pathway for pediatric rare immunodeficiency (APDS)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FDA Complete Response Letter for leniolisib indicating regulatory pathway challenge
  • December 2025Participation in Oppenheimer Movers in Rare Disease Summit showcasing HAE market leadership
  • +2 moreTrack every material event for Pharming Group N.V. as it happens. Explore monitoring →
Get alerted when Pharming Group N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Berinert/C1-esterase inhibitorPlasma-derived C1-esterase inhibitor for acute HAE attacks→CinryzeC1-esterase inhibitor concentrate for hereditary angioedema prophylaxis→Kallikrein inhibitorsAlternative mechanism for HAE and rare disease management→

Compare Pharming Group N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pharming Group N.V. operates in Biopharmaceuticals - Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Rare Diseases research →
NEW · MCP server

Ask your AI assistant about Pharming Group N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pharming Group N.V. and its top competitor on Cyborg Score”
“What did Pharming Group N.V. do this quarter?”
“Is Pharming Group N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Pharming Group N.V. do?+
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovativ...
What is Pharming Group N.V.'s Cyborg Score?+
Pharming Group N.V. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pharming Group N.V.'s main competitors?+
Named competitors include Berinert/C1-esterase inhibitor, Cinryze, Kallikrein inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Pharming Group N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pharming Group N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pharming Group N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Rare Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Pharvaris N.V.7Pharming Group N.V.